News
The approval applies to anyone aged 18 and older who has a risk of being exposed to the virus. But the FDA and the Centers ...
The use of Valneva’s chikungunya vaccine, known under the brand name Ixchiq, has been paused in elderly individuals after reports of serious adverse events (AEs) The US Food and Drug ...
Chikungunya is transmitted to humans through the bite of infected female mosquitoes, particularly Aedes aegypti and Aedes albopictus. It is a ...
The CDC recommends the vaccine pause while it investigates “serious adverse events,” including neurologic and cardiac events. As of May 7, 17 serious events, including two deaths, have been reported ...
With this extension, IXCHIQ ®, the first vaccine against the ... M.D., Chief Medical Officer of Valneva, said, “Given the substantial risk that chikungunya presents to individuals residing ...
Valneva has been awarded funding from the Coalition for Epidemic Preparedness Innovations (CEPI) and EU to expand access to its recently approved vaccine for chikungunya, a potentially life ...
17 serious adverse events, including two deaths, reported among adults 62–89 who received the Ixchiq vaccine. Ixchiq was approved in 2023 and has been distributed globally with 80,000 doses ...
The Centers for Disease Control and Prevention and the Food and Drug Administration posted notices late last week on the vaccine, Valneva’s Ixchiq. Chikungunya, spread by the bites of infected ...
(Reuters) - The U.S. Centers for Disease Control and Prevention has accepted its advisory panel's recommendations on vaccines ...
Europe Reviews Valneva's Chikungunya Vaccine After Reports of Serious Side Effects (Reuters) -The European Union's health regulator said on Wednesday it was reviewing French drugmaker Valneva's ...
The EMA now advises against using the drug for people aged over 65 after 17 serious adverse effects were recorded in this age ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results